Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies

News provided by

Jun 18, 2014, 12:16 ET

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/drug_discovery_outsourcing_world_market_forecast_2014_2024_future_prospects_leading_companies.html

Report Details

Drug discovery outsourcing - discover trends and segments with highest revenue potential

What does the future hold for drug discovery outsourcing? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our new study is your guide to the potential of those pharmaceutical services. It lets you assess projected sales at world market, submarket and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions.

In our investigation you also see qualitative analyses, new R&D and business developments. Our 194 page report provides 152 tables, charts, and graphs. Read the full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience, Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium
- Dr. Mark Craighead, Director of Scientific Strategy, Redx Pharma

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of four outsourcing submarkets at world level to 2024:
• Chemical services
• Biological services
• Lead optimisation
• Lead identification and screening

With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery.

What are the prospects in leading regions and countries?

Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients.

In our study you will find individual revenue forecasts to 2024 for 12 national markets:
• US
• Japan
• UK
• Germany
• France
• Spain
• Italy
• China
• India
• Brazil
• Russia
• South Korea
• RoW

Emerging economies have large, highly educated workforces and competitive price regimes. Therefore countries like China and India continue to rapidly emerge as important outsourcing destinations for research and manufacturing.
Greater uptake of existing technology worldwide will also stimulate the industry and market.

Leading companies and potential for market growth

Overall world revenue for that market area will reach $14.9bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what services and organisations hold greatest potential. See profiles of 13 leading companies, including these:
• Albany Molecular Research (AMRI)
• Aptuit
• Charles River Laboratories
• Covance
• Cyprotex
• Domainex
• Evotec
• Galapagos
• GenScript
• Pharmaceutical Product Development (PPD)
• Quintiles
• WIL Research Laboratories
• WuXi AppTec

In general, a company profile gives you the following information
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A) and collaborations.
• Drug discovery revenue forecasts to 2024

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect outsourced drug discovery?

Our new report discusses issues and events affecting early-stage drug development. You will find discussions, including qualitative analyses:
• Increasing focus on biologic drugs continues to provide CROs with expansion opportunities
• Changing R&D models in the pharmaceutical industry
• Progress in target identification, validation, chemistry, biology and ADMET screening
• Emerging markets offering reprieve from the effects of cost pressures and declining R&D budgets

Also, you find coverage of these aspects:
• Regional expansion, competition and CRO consolidation
• Niche CROs and virtual pharmaceutical companies
• Technology transfer and intellectual property (IP)
• Competition from private-public partnerships

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies report helps you

In summary, our 194 page report gives you the following knowledge:
• Revenues forecasts to 2024 for the overall world drug discovery outsourcing market and 4 submarkets - discover the industry's prospects, finding promising places for investments and revenues
• Assessment of 13 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for 12 national markets - US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China, South Korea and RoW.
• View opinions from our survey, seeing interviews with authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

1. Executive Summary

1.1 Market Highlights
1.2 Overview of the Report Content
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Drug Discovery Outsourcing

2. An introduction to Drug Discovery Outsourcing

2.1 What is Outsourcing?
2.1.1 Drug Discovery Outsourcing: Forming Global Networks
2.2 Why Outsource Drug Discovery?
2.2.1 The Move from Tactical to Strategic Outsourcing
2.2.2 The Advantages of Drug Discovery Outsourcing
2.2.3 Technological Advances Making In-House Drug Development Unsustainable
2.2.4 Emerging Markets Offering Reprieve from the Effects of Cost Pressures and Declining
R&D Budgets
2.2.5 Strategic Partnerships: A Prequel to CRO Acquisition
2.2.6 Outsourcing to Improve Efficiency and Reduce Time-to-Market
2.3 Typically Outsourced Processes in Drug Discovery
2.4 A Paradigm Shift for Drug Development
2.4.1 Collaboration with Academia is Key for Pipeline Replenishment
2.5 Quality of Service is Integral for CRO Growth
2.6 Outsourcing: Reducing the Cost of Innovation

3. Global Drug Discovery Outsourcing Market 2014-2024

3.1 Drug Discovery Outsourcing: Global Market Overview
3.1.1 The Global Drug Discovery Outsourcing Market in 2012 and 2013
3.2 Global Drug Discovery Outsourcing: Market Forecast 2014-2024
3.2.1 Changing Market Shares by Sector 2014-2024
3.3 Global Chemistry Services Outsourcing Market 2014-2024
3.3.1 The Global Chemistry Services Outsourcing Market in 2012 and 2013
3.3.1.1 Libraries: Important for Cost Reduction and Time Efficiency
3.3.1.2 Custom Synthesis: A Major Driver for Long-Term Strategic Partnerships
3.3.1.3 Building Blocks: Promotes Efficiency of Drug Synthesis
3.3.2 Global Chemistry Services Outsourcing Forecast 2014-2024
3.4 Global Biology Services Outsourcing Market 2014-2024
3.4.1 The Global Biology Services Outsourcing Market in 2012 and 2013
3.4.1.1 Target Identification
3.4.1.2 Target Validation
3.4.2 Global Biology Services Outsourcing Forecast 2014-2024
3.5 Global Lead Optimization Market 2014-2024
3.5.1 The Global Lead Optimization Market in 2012 and 2013
3.5.1.1 ADMET Screening: To Prevent Late Stage Failure of Clinical Trials
3.5.2 Global Lead Optimisation Forecast 2014-2024
3.6 Global Lead Identification and Screening Outsourcing Market 2014-2024
3.6.1 The Global Lead Identification and Screening Outsourcing Market in 2012 and 2013
3.6.1.1 Methodologies of Lead Identification
3.6.2 Global Lead Identification and Screening Outsourcing Market: Forecast 2014-2024

4. Leading National Markets 2014-2024

4.1 Drug Discover Outsourcing - A Game of Supply versus Demand
4.1.1 The Global Distribution of Drug Discovery Outsourcing in 2012 and 2013
4.2 Leading National Markets: Forecast 2014-2024
4.2.1 Changing Market Shares by Region 2014-2024
4.3 Regional Drug Discovery Outsourcing Markets: Analysis and Forecasts 2014-2024
4.3.1 United States: Patent Expiries Boosting Pipeline Investment
4.3.2 The EU5 Markets
4.3.2.1 EU5: Changing Market Shares by Country 2014-2024
4.3.2.2 Germany: Europe's Largest Drug Discovery Outsourcing Market
4.3.2.3 UK: A Service-Oriented Market
4.3.2.4 France: Market Dominated by Large CROs
4.3.2.5 Italy: Heavy Investment from Multinational CROs will Drive Growth
4.3.2.6 Spain: An Immature Market with Potential
4.3.3 Japan: An Aging Population Putting a Strain on Pharma
4.3.4 The BRIC Nations: Rapid Growth will Fuel the Global Market
4.3.4.1 China: Rapid Market Expansion Fuelled by Acquisitions
4.3.4.2 India: R&D Infrastructure Needed for Market Boom
4.3.4.3 Brazil: The Largest Pharma Market in Latin America
4.3.4.4 Russia: A Highly Fragmented Market
4.3.5 South Korea: A Pharmaceutical Powerhouse of the Future

5. Leading Companies Offering Drug Discovery Services

5.1 Drug Discovery Outsourcing: An Expanding Marketplace
5.2 What Makes a Successful Contract Research Organisation?
5.2.1 A Business Model that Encourages Cost Reduction
5.2.2 A Workforce with Proven Expertise
5.2.3 Good Working Relationship: A Requisite for Outsourcing
5.2.4 Adequate Intellectual Property Protection
5.2.5 Huge Emphasis is placed on Communication and Timeliness
5.3 Leading Companies in the Drug Discovery Outsourcing Arena
5.4 Albany Molecular Research (AMRI)
5.4.1 SMARTSOURCING for Enhanced Decision-Making
5.4.2 AMRI's Drug Discovery Services
5.4.3 AMRI's Licensing Agreements and Drug Discovery Collaborations
5.4.4 AMRI Revenue Forecast 2014-2024
5.5 Aptuit
5.5.1 INDIGO: Aptuit's Accelerated Drug Development Programme
5.5.2 Strategic Partnerships Strengthening Aptuit's Outlook
5.6 Charles River Laboratories
5.6.1 Charles River: Strong Sales of Research Models Boosts Revenue
5.6.2 Charles Rivers: Corporate Restructuring to Maximise Efficiency
5.6.3 Charles River: Revenue Analysis and Forecast 2014-2024
5.7 Covance
5.7.1 Refocusing Early-Stage Efforts
5.7.2 Covance Strategic Partnerships
5.7.3 Covance: Revenue Analysis and Forecast 2014-2024
5.8 Cyprotex: An ADME-Tox Service Provider
5.8.1 Cyprotex: Revenue Analysis and Forecast 2014-2024
5.9 Domainex: Pipeline Products Showing Promise
5.10 Evotec: Discovery Alliances and Development Partnerships
5.10.1 Action Plan 2016 - Leadership in Drug Discovery Solutions
5.10.2 Evotec: Revenue Analysis and Forecast 2014-2024
5.11 Galapagos
5.11.1 Galapagos - Recent Activity
5.12 GenScript: A Biology-Focused Research Company
5.12.1 GenScript: Agreements and Partnerships
5.13 Pharmaceutical Product Development (PPD): A Leading CRO
5.13.1 PPD: Agreements, Strategic Partnerships and Private Merger
5.13.2 PPD's Expansion in the Asian Markets
5.13.3 PPD and BioDuro: A Key Acquisition for Chinese Market Dominance
5.14 Quintiles: The World's Largest Biopharmaceutical Services Company
5.14.1 Quintiles: Acquisition of Advion Bioanalytical Labs
5.14.2 Quintiles - New Developments
5.14.3 Quintiles: Revenue Analysis and Forecast 2014-2024
5.15 WIL Research Laboratories
5.16 WuXi AppTec: China's Leading CRO
5.16.1 WuXi AppTec: Revenue Analysis, 2008-2012
5.16.2 WuXi's Strategic Partnerships and Recent Developments
5.16.3 WuXi AppTec: Revenue Forecast 2014-2024

6. Drug Discovery Outsourcing Market: Analysis and Trends

6.1 SWOT Analysis of the Drug Discovery Outsourcing Market 2014-2024
6.2 Strengths
6.2.1 Cost Reduction: A Central Driver for Outsourcing
6.2.2 Efficient Turnaround Times is Key for the Growth of Outsourcing
6.2.3 Acquisitions and Mergers allows for a more Comprehensive Service Provision
6.3 Weaknesses
6.3.1 The Negative Effects of Falling R&D Spending
6.3.2 Market Saturation and Poorly-Defined Service Offerings
6.4 Opportunities
6.4.1 The Available Scope for the Expansion of CROs
6.4.2 Targeted Therapies: Advances in Biologics and Orphan Drugs
6.4.3 Orphan Drug Development: An Opportunity for Higher Premiums
6.4.4 The Rise of Biologics and Biosimilars
6.4.5 The Multi-directional Expansion of CROs
6.4.6 The Rise of Virtual Pharma Companies
6.5 Threats
6.5.1 A Competitive Market Causing Smaller CROs to Miss Out
6.5.2 Private-Public Alliances May Become a Threat to Drug Discovery Outsourcing
6.5.3 Intellectual Property Leaks and the Challenges of Technology Transfer
6.5.4 Resource Sharing by Pharma Companies Could Restrain CRO Growth
6.6 Porter's Five Force Analysis of the Drug Discovery Outsourcing Market
6.6.1 Power of Suppliers: Medium
6.6.2 Threat of Substitutes: Medium
6.6.3 Rivalry among Competitors: High
6.6.4 Bargaining Power of Buyers: High
6.6.5 Threat of New Entrants: Medium

7. Expert Opinions

7.1 Interview with Dr Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium
7.1.1 Current State of the Drug Discovery Outsourcing Industry
7.1.2 Drug Discovery Collaborations between Pharma and Academia
7.1.3 Academic Research: A Restraint to CRO Growth?
7.1.4 The Changing Outsourcing Model: Implications for Pharma R&D
7.1.5 The Move towards Shared Risk Partnerships
7.1.6 Hot Therapeutic Areas in Drug Discovery
7.1.7 Views on the Future Prospects of the Market
7.2 Interview with Dr Mark Craighead, Director of Scientific Strategy, Redx Pharma
7.2.1 Changes in the Industry's Pricing Model
7.2.2 Redx Pharma's Services and Growth Plans
7.2.3 Is Outsourcing Earlier the Key to Solving Pharma's R&D Problems?
7.2.4 Appealing Therapeutic Areas and the Role of the Asian Markets

8. Conclusion

8.1 Market Overview
8.2 A Move towards Biology Services
8.3 The Rise of the Asian Outsourcing Industry
8.4 Unmet Therapeutic needs will Stimulate Drug Discovery Drive
8.5 Alliances and Collaborations Will Continue to Dominate the Market

List of Tables

Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2013
Table 2.2 Selected Drug Discovery Outsourcing Alliances 2012- 2013
Table 2.3 Selected Drug Discovery Outsourcing Alliances 2009- 2012
Table 3.1 PhRMA's Historical Estimate for its Member's R&D Spending ($bn)
Table 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn), Market Shares (%) and Growth (%) by Sector, 2012 and 2013
Table 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%) by Sector, 2012-2017
Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2017-2024
Table 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017, 2017-2024, and 2012-2024
Table 3.6 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024
Table 3.7 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2024
Table 3.8 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 3.9 The Biology Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 3.10 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 3.11 Selected Drug Discovery Lead Optimisation Partnerships
Table 3.12 Selected Methods for Sourcing Lead Compounds, 2013
Table 3.13 The Global Lead Identification and Screening Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) and Growth (%) by Region, 2012 and 2013
Table 4.2 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2012-2017
Table 4.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2017-2024
Table 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017, 2017-2024, and 2012-2024
Table 4.5 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012, 2017, 2024
Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.7 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Market Share (%) and CAGR (%), 2012-2024
Table 4.9 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2012-2017
Table 4.10 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2017-2024
Table 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2012-2017, 2017-2024, and 2012-2024
Table 4.12 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012, 2017, 2024
Table 4.13 The German Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 4.15 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.16 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 4.17 The French Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.18 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 4.19 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.20 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.22 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 4.23 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.24 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.25 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.26 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.27 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.28 The Indian Population: Demographic Forecast by Age Group (%), 2015, 2020, 2025
Table 4.29 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.30 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.31 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.32 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.33 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 4.34 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024
Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m, AGR %), 2008-2012
Table 5.2 AMRI: Services offered and Descriptions, 2013
Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage
Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.5 Aptuit: Services Offered and their Descriptions, 2013
Table 5.6 Charles River Laboratories: Selected Services Provided, 2013
Table 5.7 Charles River: Historical Revenue ($m, AGR %), 2010-2012
Table 5.8 Charles River: Historical Revenue ($m) by Segment, 2009-2012
Table 5.9 Charles River: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.10 Covance: Historical Revenue ($bn) by Business Segment, 2009-2012
Table 5.11 Covance: Early Development Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.12 Selected Cyprotex Partnerships, 2013
Table 5.13 Cyprotex: Historical Revenue ($m) by Region, 2010-2012
Table 5.14 Cyprotex: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.15 Domainex's Collaborations and Partnerships, 2013
Table 5.16 Evotec: Historical Revenue ($m, AGR %), 2008-2012
Table 5.17 Evotec Action Plan 2016: Leadership in Drug Discovery Solutions
Table 5.18 Evotec: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.19 Galapagos Pipeline Projects and Development stages, 2013
Table 5.20 Galapagos: Historical operating Income ($m) by Business Sector, 2011 and 2012
Table 5.21 Genscript: Services Offered and Descriptions, 2013
Table 5.22 Quintiles: Historical Revenue ($bn, AGR %), 2008-2012
Table 5.23 Quintiles: Revenue Forecast ($bn, AGR %, CAGR%), 2012-2024
Table 5.24 WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2013
Table 5.25 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012
Table 5.26 WuXi AppTec: Laboratory Services Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 6.1 Drug Discovery Outsourcing: Market Drivers, 2014-2024
Table 6.2 Drug Discovery Outsourcing: Market Restraints, 2014-2024
Table 6.3 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2014-2024
Table 6.4 NIH Biomarker Definitions, 2013
Table 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn, CAGR%): 2012, 2017, 2020, 2024
Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024
Table 8.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024

List of Figures

Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013
Figure 2.2 Typical Stages of the Drug Development Cycle
Figure 3.1 PhRMA's Historical Estimate for its Member's R&D Spending ($bn)
Figure 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Sector, 2012 and 2013
Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2017
Figure 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2017-2024
Figure 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017
Figure 3.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2017-2024
Figure 3.7 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2024
Figure 3.8 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024
Figure 3.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2012
Figure 3.10 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2017
Figure 3.11 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2024
Figure 3.12 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.13 The Biology Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.14 An Overview of ADMET Screening in Drug Discovery
Figure 3.15 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.16 Typical Steps in the Lead Screening Process
Figure 3.17 The Global Lead Identification and Screening Market: Revenue Forecast ($bn), 2012-2024
Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Region, 2012
Figure 4.2 US, EU5, and Japan Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.3 China, India, South Korea, Brazil, and Russia Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017
Figure 4.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2017-2024
Figure 4.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2024
Figure 4.7 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012
Figure 4.8 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017
Figure 4.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2024
Figure 4.10 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.11 Germany, UK, France, Italy, and Spain Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2024
Figure 4.13 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012
Figure 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.15 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.16 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.17 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.18 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.19 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060
Figure 4.20 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.21 Chinese Demographics: Over 65 Population and Forecast (millions), 1950, 2010, 2050
Figure 4.22 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.23 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.24 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.25 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2008-2012
Figure 5.2 Albany Molecular Research (AMRI): Revenue Forecast ($m), 2012-2024
Figure 5.3 Charles River: Historical Revenue ($m), 2010-2012
Figure 5.4 Charles River: Historical Revenue ($m) by Segment, 2012
Figure 5.5 Charles River: Revenue Forecast ($m), 2012-2024
Figure 5.6 Covance: Historic Revenue ($bn), 2009-2012
Figure 5.7 Covance: Revenue ($bn) by Segment, 2012
Figure 5.8 Covance: Early Development Revenue Forecast ($m), 2012-2024
Figure 5.9 Cyprotex: Historical Revenue ($m), 2010-2012
Figure 5.10 Cyprotex: Revenue Shares (%) by Region, 2012
Figure 5.11 Cyprotex: Revenue Forecast ($m), 2012-2024
Figure 5.12 Evotec: Historical Revenue ($m), 2008-2012
Figure 5.13 Evotec: Revenue Forecast ($m), 2012-2024
Figure 5.14 Galapagos: Revenue Share (%) by Business Sector, 2012
Figure 5.15 Quintiles: Historical Revenue ($bn), 2008-2012
Figure 5.16 Quintiles: Revenue Forecast ($bn), 2012-2024
Figure 5.17 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012
Figure 5.18 WuXi AppTec: Laboratory Services Revenue Forecast ($m), 2012-2024
Figure 6.1 Porter's Five Force Analysis of the Drug Discovery Outsourcing Market, 2013
Figure 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn): 2012, 2017, 2020, 2024
Figure 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024
Figure 8.3 Global Over-60 Population Forecast (%): 1950, 2009, 2050
Figure 8.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024

Companies Listed

Abbott
Accugenix
Advion Bioanalytical
Albany Molecular Research Inc (AMRI)
Andromeda Biotech (Teva)
Apredica (Cyprotex)
Aptuit
Argenta (Galapagos)
AstraZeneca
Bayer
Behrman Capital
BioCity
BioDuro (PPD)
BioFocus (Galapagos)
Biopontis Alliance
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Carlyle Group
Catalent Pharma Solutions
Cerebricon (Charles River)
Charles River Laboratories
ChemBridge
ChemDiv
Compound Focus (Evotec)
Covance
Crucell
Cyprotex
Discovery Partners International
Domainex
Dow AgroSciences
Dow Chemical Company
Elan
Eli Lilly
Evotec
Fidelity Growth Partners India (FGPI)
Fidelta (Galapagos)
Furiex Pharmaceuticals
Galapagos
Genentech
GenScript
GlaxoSmithKline (GSK)
Glycoform
Great Lakes Chemical Corporation
Hangzhou Tigermed Consulting
Hellman & Friedman
Hypha Discovery
i3 Research (inVentiv Health)
ICON
Inpharmatica
InSphero
InVentiv Health
Johnson & Johnson (J&J)
Janssen Pharmaceutical Group
Kinaxo
Knopp Biosciences
ICON
Immatics
JOINN Laboratories
Laurus Labs
Lonza
MAB Discovery
MedImmune
Merck & Co.
Microsoft
Midwest BioResearch (WIL Research)
Millipore
Novartis
Ono Pharmaceutical
Oxford Asymmetry International
Parexel
Peking Union Lawke Biomedical Development Limited (PUL)
Pfizer
Myriad RBM
Pharmaceutical Product Development (PPD)
Pharmidex
PharmaNet Development Group (inVentiv Health)
Pharminox
Piedmont Research Center (Charles River)
PRA International
ProSkelia
ProStrakan
Proteome Sciences
Proteros Biostructures GmbH (Proteros)
ProtonMedia
Quintiles
Ricerca Biosciences (WIL Research)
Roche
Samsung
Sanofi
Sareum Holdings Plc
Servier
ShangPharma Corporation
Shionogi
Sirius Analytical
Solvo Biotechnology
Swiss Pharma Contract
Sygnature Discovery
SYNthesis Med Chem
Taijitu Biologics
Takeda
Teva
The Dow Chemical Company
Tibotec
TRAC Microbiology
TransGenic
UCB
VitualScopics
WIL Research Laboratories
WuXi AppTec
WuXi PharmaTech

Other Organisations Mentioned in This Report

American Cancer Society
Associação Brasileira de CROs (Abracro)
Beijing Genomics Institute
Bundesverband Medizinischer Auftragsinstitute (BVMA)
CHDI Foundation
Dundee University
Food and Drug Administration (US FDA)
Indiana Clinical and Translational Sciences Institute (CTSI)
Johns Hopkins University
Massachusetts General Hospital
National Institute for Population and Social Security Research (IPSS)
National Institutes of Health (NIH)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Russian Corporation of Nanotechnologies
Southwestern Medical Center
The European Innovative Medicine Initiative (IMI)
The European CRO Federation (EUCROF)
The Institute of Cancer Research
The Organization for Economic Cooperation and Development (OECD)
University of Manchester
University of North Carolina
Wellcome Trust
World Health Information Science Consultants (WHISCON)
World Health Organization (WHO)
World Trade Organization (WTO)